Department of Periodontics, Government Dental College and Research Institute, Bangalore, India.
Aust Dent J. 2013 Jun;58(2):156-62. doi: 10.1111/adj.12042.
Simvastatin (SMV) is a specific competitive inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. Statins have recently been shown to promote bone formation. This study was designed to investigate the effectiveness of SMV 1.2% in an indigenously prepared biodegradable controlled release gel as an adjunct to scaling and root planing (SRP) in the treatment of smokers with chronic periodontitis.
Forty patients were categorized into two treatment groups: SRP plus SMV 1.2% and SRP plus placebo. Clinical parameters were recorded at baseline and at 3, 6 and 9 months; they included modified sulcus bleeding index (mSBI), probing depth (PD) and clinical attachment level (CAL). At baseline, after 6 months and 9 months, radiologic assessment of intrabony defect (IBD) fill was done using computer-aided software.
Mean probing depth reduction and mean clinical attachment level gain was greater in the SMV group than the placebo group at all visits. Furthermore, significantly greater mean percentage of bone fill was found in the SMV group (32.37 ± 10.23%) compared to the placebo (4.18 ± 5.39%).
There was a greater decrease in mSBI and PD and more CAL gain with significant IBD fill at sites treated with SRP plus locally delivered SMV in smokers with chronic periodontitis.
辛伐他汀（SMV）是 3-羟基-2-甲基戊二酰辅酶 A 还原酶的特异性竞争性抑制剂。最近的研究表明他汀类药物能促进骨形成。本研究旨在探讨自制生物可降解控释凝胶中 SMV1.2%作为辅助治疗在慢性牙周炎吸烟者中与洁治和根面平整（SRP）联合应用的效果。
将 40 名患者分为两组：SRP 加 SMV1.2%和 SRP 加安慰剂。基线时、第 3、6、9 个月记录临床参数，包括改良龈沟出血指数（mSBI）、探诊深度（PD）和临床附着水平（CAL）。基线时、第 6 个月和第 9 个月，使用计算机辅助软件评估骨内缺损（IBD）的填充情况。
在所有访视中，SMV 组的平均探诊深度减少和平均临床附着水平增加均大于安慰剂组。此外，SMV 组的平均骨填充百分比（32.37±10.23%）明显大于安慰剂组（4.18±5.39%）。
在慢性牙周炎吸烟者中，与单独接受 SRP 治疗相比，局部给予 SMV 治疗可使 mSBI 和 PD 显著降低，CAL 显著增加，IBD 明显填充。
